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Past, Present, and 
Future of Japanese 
Encephalitis
To the Editor: We are writing in 
response to the perspective on Japanese 
encephalitis (JE) by Erlanger et al. (1). 
Growing  awareness  is  encouraging, 
yet because JE is a largely neglected 
disease,  information  is  often  contra-
dictory  or  not  readily  available.  We 
would like to supplement the authors’ 
review with clarification on available 
vaccines and actions countries are tak-
ing to evaluate and control JE.
There  is  room  for  improvement 
or expansion on collecting and report-
ing JE surveillance data. However, as 
vaccine  availability  increases,  many 
countries are eager to determine the 
impact of JE and to make informed 
decisions on immunization programs. 
For  example,  surveillance  in  Indo-
nesia  from  2005  through  2006  con-
firmed  human  cases  throughout  the 
country (2). In Cambodia, JE surveil-
lance commenced in 2006, and an im-
munization program is being planned 
(2). Regional JE laboratory networks 
established by the World Health Or-
ganization are also helping countries 
gather this information by strengthen-
ing diagnostic capacity.
Cambodia plans to introduce the 
live,  attenuated  SA  14-14-2  vaccine 
from  China’s  Chengdu  Institute  of 
Biological Products. This vaccine has 
recently become internationally avail-
able and is increasingly replacing the 
inactivated, mouse brain–derived vac-
cine in Asia. A single dose of the SA 
14-14-2  vaccine  demonstrated  96% 
efficacy after 5 years (3), and the In-
stitute’s commitment to an affordable 
price  for  developing  countries  has 
broadened accessibility (4). The gov-
ernment  of  India  introduced  the  SA 
14-14-2 vaccine in 2006, and nearly 
50 million children 1–15 years of age 
have been reached through vaccination 
campaigns and routine immunization. 
The vaccine also is available through 
public programs or private markets in 
China, Nepal, South Korea, Sri Lanka, 
and Thailand.
JE  vaccine  candidates  in  late-
stage  development  for  children  in-
clude a live, attenuated chimeric virus 
vaccine and an inactivated, Vero cell–
derived vaccine, each based on the SA 
14-14-2  virus  strain. Additionally,  2 
inactivated,  Vero–cell  derived  vac-
cines based on the Beijing-1 strain are 
being developed in Japan (5).
New vaccine development, along 
with progress in surveillance and im-
munization, offers promise for sustain-
able control of clinical JE. To achieve 
this, global partners are working to-
gether to develop a strategic plan for 
JE control by 2015 (6).
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